The SmartTRAK analyst team is expanding and we are looking for an experienced and motivated individual who would like to manage one or more of our Advanced Wound Care modules, with a focus on the European markets. As you know, all of our SmartTRAK analysts are former marketing, business development or competitive intelligence professionals with one of the major medical device manufacturers and, in fact, most have come to us via recommendations from our subscribers. We believe that having a person of this caliber with relevant experience and deep insight on the market is a tremendous value-add to the SmartTRAK platform.

Learn More and Apply

SmartTRAK Subscribers: See only news for the Markets, Modules and Segments and now TYPES of content that you care about!

Have you ever wished that you could customize your SmartTRAK Daily Updates Email so that you can see ONLY news about the SmartTRAK Markets, Modules & Segments as well as Type of content that you care about (like skipping all the Patent updates)?

And that you could save yourself time from scrolling through all the Markets, Modules and Segments that your company subscribes to? 

SmartTRAK was cited once again as a trusted source for data in a press release from Smith & Nephew entitled "Smith & Nephew meniscal knee repair technology delivers 0% re-operation rate and 100% meniscal healing at six months shows first ever study of horizontal cleavage tears".

Robotic-assisted surgery was a hot topic of discussion at this year’s ODT Forum. SmartTRAK Senior Analyst for Computer-Assisted Surgery, Elise Wolf, participated in a panel discussion entitled “Tech Talk: An Overview of the Growing Role of Additive Manufacturing and Robotic Surgery,” along with Mitch Foster, CEO of Mindset Medical and former CEO and Co-Founder of Excelsius Surgical. The session was moderated by Dawn Lissy, President & Founder of Empirical Testing.

The discussion focused on current market dynamics and future directions in robotic platforms and other enabling technologies in orthopedic and spine surgery. An excerpt of the panel discussion is provided below.

SmartTRAK is excited to be attending the Society of Neurointerventional Surgery’s (SNIS) 16th Annual Meeting in Miami, Florida from July 22-25, 2019. Anne Staylor, Managing Editor, Business Intelligence and Senior Director, Advanced Technologies will be covering the latest news at the conference, and will be providing updates on key studies, trends, and technologies affecting the market for ischemic and hemorrhagic stroke devices. 

BioMedGPS, developer of SmartTRAK Business Intelligence, has been recognized by the Orange County Business Journal (OCBJ) as one of the largest women-owned firms in Orange County, CA.

SmartTRAK identifies trends to watch in Spine

By most accounts, the Spine market has stabilized with modest low single-digit growth expected this year. Medtronic CEO Omar Ishrak agrees that the Spine market seems to have stabilized and is starting to inch back up. However, he suggests that it is still slower than a year or two ago as price declines are now offsetting procedure growth, resulting in flat to low single-digit to growth. For 2019, Needham analysts are modeling 2% spine market growth with overall orthopedic market growth of 3.4%.

New strategic alliance expands SmartTRAK market research capabilities

BioMedGPS, developer of SmartTRAK Business Intelligence, is excited to announce a new strategic partnership with Quomeda, a widely respected international healthcare research consultancy firm located in the UK.  Through this new alliance, SmartTRAK has expanded its suite of strategic advisory services globally to include custom consulting as well as provider, hospital and procedural volume data.

SmartTRAK hosted a tour, dinner reception and briefing at Gothenburg's Universeum before EWMA 2019. Attendees were treated to a private tour of the Universeum and the Ocean Zone prior to dinner and the briefing, entitled Trends, Opportunities and Innovations in Advanced Wound Care, with a special focus on the European market.

OrthogenRx CEO & Founder Michael Daley talks about the Company’s new 3-injection HA product, TriVisc and what will come next.

Michael Daley, CEO & Founder of OrthogenRx, a US medical device company focused on treatments for musculoskeletal conditions, talked about TriVisc, the Company’s new 3-injection hyaluronic acid (HA) product for knee osteoarthritis, as well as the future at OrthogenRx, in an interview with SmartTRAK at the American Academy of Orthopaedic Surgeons 2019 Annual Meeting held March 12-14, 2019 in Las Vegas, NV.

What is the rational for OrthogenRx to bring TriVisc now to a very crowded 3-injection HA segment?

To have a presence in the entire US HA market, OrthogenRx aims to provide...